STIM — Neuronetics, Inc.
8 mentions in the last 24 hours · 0.04% of all mentions
Why people talked about STIM (2026-11-05)
- Neuronetics reported Q3 earnings that beat EPS estimates by $0.07, with revenue rising 12.5% to $42.0M.
- The company announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) and released its Q3 2026 earnings call transcript.
- STIM shares advanced alongside other healthcare stocks, though the 10-Q filing highlighted a going-concern doubt regarding a projected March 2027 covenant shortfall.
| GDELT | 5 | news |
| Bluesky | 2 | community |
| SEC EDGAR 8-K | 1 | filings |